Nir Messafi Portfolio

Invests via Deep Track Capita LLP | Managed by David Kroin

Invests via Deep Track Capita LLP

Managed by David Kroin

Automatically Tracked

Tracking: 0 Updated: Yesterday at 07:15 AM

Nir Messafi Profile

Nir Messafi is a dynamic entrepreneurial founder with deep expertise in technology-driven startups. With a background in engineering and extensive experience in software development, he has successfully launched several innovative ventures that have redefined industry standards. His commitment to fostering disruptive technologies places him at the forefront of the digital landscape. By bridging the gap between technical innovation and market needs, he plays a crucial role in shaping emerging business models across various sectors. Messafi's ability to identify growth opportunities enables him to navigate complex market challenges, making significant contributions to entrepreneurship and investment landscapes.

Investment Philosophy & Strategy

With a strong focus on innovation, Nir Messafi seeks transformative opportunities within the technology sector. His entrepreneurial spirit drives him to explore nascent markets where emerging technologies can create significant impact. Capitalizing on his engineering background and software development expertise, he targets investments that promise substantial scalability and differentiation. By understanding customer demands and aligning them with groundbreaking solutions, he positions himself strategically in competitive landscapes. This approach not only fuels growth for his ventures but also contributes to redefining industry standards through operational excellence.

Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.

Gain and growth charts are calculated per selected timeframe:

56.39%

Gain +2.81%

Monthly

0.61%

Yearly

7.6%

Drawdown

49.72%

$5.27B

Equity

Holdings

$5.27B

Investment

$3.84B

$1.88B

Profit +$169.8M

Realized

$445.29M

Unrealized

$1.43B

Dividends

$2.8M

Goals

Avg. 36% completed goals

Yearly

Gain > 5%

2026

Yearly

Gain < 20%

2026

72%

Today

Compared To Yesterday

Gain

2.81%

Profit

$169.8M

Win %

67%

This Week

Compared To Last Week

Gain

3.33%

Profit

$169.8M

Win %

67%

This Month

Compared to last month

Gain

4.03%

Profit

$204.38M

Win %

67%

This Year

Compared to last year

Gain

-5.59%

Profit

-$94.54M

Win %

71%

Gainers
Losers

ALMS Alumis Inc.

+15.55%

+$22.01M

CMPS Compass Pathways plc Depositary Receipt

+5.87%

+$8.15M

MLTX MoonLake Immunotherapeutics

+5.3%

+$6.02M

CLDX Celldex Therapeutics Inc.

+4.37%

+$1.68M

VSTM Verastem Inc.

+4.06%

+$918,536

TNGX Tango Therapeutics Inc.

+3.76%

+$3.08M

ENTA Enanta Pharmaceuticals Inc.

+3.39%

+$763,178.13

ATAI AtaiBeckley Inc.

+3.16%

+$1.44M

XFOR X4 Pharmaceuticals Inc.

+3.09%

+$760,744.2

CRVS Corvus Pharmaceuticals Inc.

+2.85%

+$822,207.87

OCUL Ocular Therapeutix Inc.

+2.76%

+$4.72M

DFTX Definium Therapeutics, Inc.

+2.65%

+$1.92M

IMVT Immunovant Inc.

+2.25%

+$8.53M

KURA Kura Oncology Inc.

+2.14%

+$502,272.98

ORKA Oruka Therapeutics, Inc.

+2.07%

+$2.89M

BCAX Bicara Therapeutics Inc.

+1.93%

+$1.67M

VERA Vera Therapeutics Inc.

+1.81%

+$2.5M

PSNL Personalis Inc.

+1.8%

+$510,000

MANE Veradermics Inc.

+1.77%

+$835,000

BLLN BillionToOne, Inc.

+1.48%

+$73,500

COGT Cogent Biosciences, Inc.

+1.47%

+$479,998

DYN Dyne Therapeutics Inc.

+1.34%

+$480,000

IVA Inventiva S.A.

+1.32%

+$61,122.65

VRDN Viridian Therapeutics Inc.

+1.3%

+$292,728.24

CYTK Cytokinetics, Incorporated

+1.27%

+$1.21M

IMCR Immunocore Holdings plc American Depositary Receipt

+1.19%

+$656,840.56

GERN Geron Corporation

+0.88%

+$317,202.78

BMRN Biomarin Pharmaceutical Inc.

+0.74%

+$471,500

AXSM Axsome Therapeutics, Inc.

+0.55%

+$1.54M

GH Guardant Health Inc.

+0.55%

+$2.4M

IPSC Century Therapeutics, Inc.

+0.45%

+$94,877.45

PCVX Vaxcyte, Inc.

+0.36%

+$731,000

ANIP Ani Pharmaceuticals Inc.

+0.04%

+$18,000

ALGS Aligos Therapeutics Inc.

APLS Apellis Pharmaceuticals Inc.

CYBN Cybin Inc.

SLNO Soleno Therapeutics, Inc.

TERN Terns Pharmaceuticals, Inc.

MBX MBX Biosciences, Inc.

-4.67%

-$4.8M

LRMR Larimar Therapeutics Inc.

-3.61%

-$195,000

PMN ProMIS Neurosciences, Inc.

-3.27%

-$292,479.25

CRMD CorMedix Inc.

-2.46%

-$1.38M

CBIO Crescent Biopharma, Inc.

-2.29%

-$190,548.12

CNTX Context Therapeutics Inc.

-2.11%

-$222,580.65

ALKS Alkermes plc

-1.43%

-$2.3M

APGE Apogee Therapeutics Inc.

-1.31%

-$333,450

BEAM Beam Therapeutics Inc.

-1.29%

-$311,889.88

ENGN enGene Therapeutics Inc.

-1.22%

-$87,551.44

ACRS Aclaris Therapeutics, Inc.

-1.14%

-$467,250

BBIO BridgeBio Pharma, Inc.

-1.11%

-$631,083.75

SLDB Solid Biosciences Inc.

-1.11%

-$285,204.96

TARS Tarsus Pharmaceuticals Inc.

-1.05%

-$2.38M

GPCR Structure Therapeutics Inc.

-0.85%

-$1.58M

IONS Ionis Pharmaceuticals, Inc.

-0.73%

-$1.05M

JANX Janux Therapeutics Inc.

-0.73%

-$118,729

GMAB Genmab A/S Sponsored ADR

-0.63%

-$586,120

GRAL Grail, Inc.

-0.52%

-$534,067.07

LBRX LB Pharmaceuticals Inc.

-0.42%

-$402,336.48

NRIX Nurix Therapeutics Inc.

-0.18%

-$190,357.32

MAZE Maze Therapeutics Inc.

-0.17%

-$139,105.96

NUVL Nuvalent, Inc.

-0.16%

-$275,264.8

CNTA Centessa Pharmaceuticals plc American Depositary Receipt

-0.13%

-$157,902.05

Events

Dividends

Dividend Analysis

No Data

Trades 849	Longs Won 393/849 46%	Profit Factor 2.31
Profitability	Shorts Won 0/0 0%	Standard Deviation $14.15M
Average Win $8.44M	Best Trade (Jun 14) $163.08M	Sharpe Ratio -6.56
Average Loss -$3.16M	Worst Trade (Dec 31) -$47.76M	Z-Score -1.36 (82.81%)
Commissions $0	Avg. Trade Length 12m	Expectancy $2.21M

Loss Size	100%	90%	80%	70%	60%	50%	40%	30%	20%	10%
Probability of Loss	<0.01%	<0.01%	<0.01%	<0.01%	<0.01%	<0.01%	<0.01%	<0.01%	<0.01%	<0.01%
Consecutive Losing Trades	1,669	1,503	1,336	1,169	1,002	835	668	501	334	167